605177 东亚药业
已收盘 02-03 15:00:00
资讯
新帖
简况
东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%
证券之星 · 02-02 17:43
东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%
原料药龙头东亚药业预亏近亿,转型之路仍崎岖
新浪证券 · 01-30
原料药龙头东亚药业预亏近亿,转型之路仍崎岖
每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿
证券之星 · 01-25
每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿
东亚药业去年预亏或高达9000万元,转型效果未达预期
新京报 · 01-23
东亚药业去年预亏或高达9000万元,转型效果未达预期
东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元
智通财经 · 01-22
东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元
每周股票复盘:东亚药业(605177)预计2025年净利润为负值
证券之星 · 01-18
每周股票复盘:东亚药业(605177)预计2025年净利润为负值
东亚药业最新公告:预计2025年净利润亏损
证券之星 · 01-14
东亚药业最新公告:预计2025年净利润亏损
东亚药业跌3.55% 2020年上市2募资共15.74亿
中金财经 · 01-12
东亚药业跌3.55% 2020年上市2募资共15.74亿
每周股票复盘:东亚药业(605177)股东户数增1.84%,可转债转股1,154,070股
证券之星 · 01-11
每周股票复盘:东亚药业(605177)股东户数增1.84%,可转债转股1,154,070股
东亚药业(605177)12月31日股东户数1.06万户,较上期增加1.84%
证券之星 · 01-05
东亚药业(605177)12月31日股东户数1.06万户,较上期增加1.84%
每周股票复盘:东亚药业(605177)东亚转债或触转股价格修正条件
证券之星 · 01-02
每周股票复盘:东亚药业(605177)东亚转债或触转股价格修正条件
东亚药业(605177)披露关于“东亚转债”预计满足转股价格修正条件的提示性公告,12月31日股价下跌0.39%
证券之星 · 2025-12-31
东亚药业(605177)披露关于“东亚转债”预计满足转股价格修正条件的提示性公告,12月31日股价下跌0.39%
每周股票复盘:东亚药业(605177)调整治理结构并优化募投项目
证券之星 · 2025-12-28
每周股票复盘:东亚药业(605177)调整治理结构并优化募投项目
东亚药业(605177)披露取消监事会并修订公司章程议案获通过,12月25日股价下跌0.06%
证券之星 · 2025-12-25
东亚药业(605177)披露取消监事会并修订公司章程议案获通过,12月25日股价下跌0.06%
东亚药业(605177)披露拟调整研发中心募投项目用途,12月19日股价上涨2.37%
证券之星 · 2025-12-19
东亚药业(605177)披露拟调整研发中心募投项目用途,12月19日股价上涨2.37%
东亚药业(605177)披露召开2025年第一次临时股东大会通知,12月09日股价下跌0.77%
证券之星 · 2025-12-09
东亚药业(605177)披露召开2025年第一次临时股东大会通知,12月09日股价下跌0.77%
每周股票复盘:东亚药业(605177)推进原料药制剂一体化战略
证券之星 · 2025-11-23
每周股票复盘:东亚药业(605177)推进原料药制剂一体化战略
每周股票复盘:东亚药业(605177)将举办2025年Q3业绩说明会
证券之星 · 2025-11-16
每周股票复盘:东亚药业(605177)将举办2025年Q3业绩说明会
东亚药业(605177)披露举办2025年第三季度业绩说明会的公告,11月11日股价上涨0.81%
证券之星 · 2025-11-11
东亚药业(605177)披露举办2025年第三季度业绩说明会的公告,11月11日股价上涨0.81%
每周股票复盘:东亚药业(605177)股东户数增至1.11万户
证券之星 · 2025-11-09
每周股票复盘:东亚药业(605177)股东户数增至1.11万户
加载更多
公司概况
公司名称:
浙江东亚药业股份有限公司
所属行业:
医药制造业
上市日期:
2020-11-25
主营业务:
浙江东亚药业股份有限公司的主营业务是化学原料药、医药中间体的研发、生产和销售。公司的主要产品是细菌类药物(β-内酰胺类和喹诺酮类)、抗胆碱和合成解痉药物(马来酸曲美布汀)、皮肤用抗真菌药物。公司是浙江省专利示范企业,并多次承担省级重大科技专项、国家火炬计划项目、省重大国际科技专项、省重点高新技术产品开发项目等。公司“β-内酰胺类药物创新团队”于2014年入选台州市重点企业技术创新团队,多次获得浙江省和台州市科技进步奖等。报告期内,公司全资子公司杭州善礼获得中国合格评定国家认可委员会(CNAS)实验室认可证书。
发行价格:
31.13
{"stockData":{"symbol":"605177","market":"SH","secType":"STK","nameCN":"东亚药业","latestPrice":21.44,"timestamp":1770102001000,"preClose":21.11,"halted":0,"volume":2220033,"delay":0,"changeRate":0.0156,"floatShares":112999999,"shares":114999999,"eps":-1.9023,"marketStatus":"已收盘","change":0.33,"latestTime":"02-03 15:00:00","open":21.56,"high":21.67,"low":21.08,"amount":47578300,"amplitude":0.0279,"askPrice":21.44,"askSize":2,"bidPrice":21.43,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-1.9023,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":5,"adr":0,"adjPreClose":21.11,"symbolType":"stock","openAndCloseTimeList":[[1770082200000,1770089400000],[1770094800000,1770102000000]],"highLimit":23.22,"lowLimit":19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":114726070,"isCdr":false,"pbRate":1.45,"roa":"--","roe":"--","epsLYR":-0.9,"committee":-0.25,"marketValue":2460000000,"turnoverRate":0.0197,"status":0,"floatMarketCap":2414000000},"requestUrl":"/m/hq/s/605177","defaultTab":"news","newsList":[{"id":"2608385220","title":"东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608385220?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:43","pubTimestamp":1770025425,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2026年1月31日公司股东户数为9845.0户,较1月20日减少145.0户,减幅为1.45%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至1月31日,化学制药行业平均股东户数为3.42万户。从股价来看,2026年1月20日至2026年1月31日,东亚药业区间涨幅为5.05%,在此期间股东户数减少145.0户,减幅为1.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200025809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2607109930","title":"原料药龙头东亚药业预亏近亿,转型之路仍崎岖","url":"https://stock-news.laohu8.com/highlight/detail?id=2607109930","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607109930?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:53","pubTimestamp":1769755980,"startTime":"0","endTime":"0","summary":" 近日,东亚药业发布2025年度业绩预告,预计全年净亏损7500万元至9000万元。尽管亏损幅度较上年有所收窄,但公司仍未能摆脱业绩持续下滑的困境。作为一家以抗菌药原料药为主业的药企,东亚药业在政策收紧、行业竞争加剧等多重压力下,正尝试通过“原料药制剂一体化”战略突围。然而,从业绩表现和转型进展来看,这条转型之路并不平坦。 面对行业环境的深刻变化,东亚药业的转型已势在必行,但道路依然漫长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-01-30/doc-inhkakfp0636110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2606498232","title":"每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2606498232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606498232?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:54","pubTimestamp":1769280850,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,东亚药业报收于22.83元,较上周的20.72元上涨10.18%。本周,东亚药业1月22日盘中最高价报23.5元,股价触及近一年最高点。东亚药业当前最新总市值26.19亿元,在化学制药板块市值排名143/150,在两市A股市值排名4915/5182。业绩披露要点东亚药业发布业绩预告,预计2025年全年扣非后净利润亏损8700万元至1.02亿元。公司公告汇总浙江东亚药业预计2025年度归属于上市公司股东的净利润为-9,000万元到-7,500万元,扣除非经常性损益后为-10,200万元到-8,700万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2605472835","title":"东亚药业去年预亏或高达9000万元,转型效果未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2605472835","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605472835?lang=zh_cn&edition=full","pubTime":"2026-01-23 19:44","pubTimestamp":1769168640,"startTime":"0","endTime":"0","summary":"1月23日,浙江东亚药业股份有限公司发布2025年业绩预告,预计实现归属于上市公司股东的净亏损为9000万元到7500万元,上年同期为净亏损1.01亿元;预计实现归属于上市公司股东的扣除非经常性损益的净亏损为1.02亿元到8700万元,上年同期为净亏损9840.82万元。上述情况导致东亚药业报告期营业收入较上年度下滑,毛利额同比减少1.08亿元。抗菌药市场压缩,业绩下滑近年来,东亚药业业绩持续承压。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261231920192880149.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261231920192880149.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769168685168036.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769168685168036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2605465793","title":"东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605465793","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605465793?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:22","pubTimestamp":1769070169,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东亚药业(605177.SH)发布2025年度业绩预告,预计2025年度实现归属于上市公司股东的净亏损7,500万元至9,000万元。报告期内,公司原料药及制剂陆续新申报了一批批件。其中获得了左氧氟沙星片的批件,为公司获批的首个制剂批件,标志着公司原料药制剂一体化发展战略取得重大突破,将进一步丰富公司产品线,有助于提升公司竞争力,促进公司持续、稳定、健康地发展。同时为公司后续制剂注册证书申报积累了宝贵的经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2604792529","title":"每周股票复盘:东亚药业(605177)预计2025年净利润为负值","url":"https://stock-news.laohu8.com/highlight/detail?id=2604792529","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604792529?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:24","pubTimestamp":1768681449,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,东亚药业报收于20.72元,较上周的21.11元下跌1.85%。本周,东亚药业1月14日盘中最高价报21.65元。东亚药业当前最新总市值23.77亿元,在化学制药板块市值排名147/150,在两市A股市值排名4972/5183。股本股东变化股东户数变动截至2026年1月10日,东亚药业股东户数为1.03万户,较12月31日减少258户,减幅2.43%。业绩披露要点业绩预告东亚药业发布业绩预告,预计2025年全年归属净利润为负值,2025年度经营业绩将出现亏损。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177"],"gpt_icon":0},{"id":"2603698965","title":"东亚药业最新公告:预计2025年净利润亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698965","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603698965?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:41","pubTimestamp":1768376506,"startTime":"0","endTime":"0","summary":"东亚药业(605177.SH)公告称,预计2025年度归属于上市公司股东的净利润为负值,经营业绩将出现亏损。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177"],"gpt_icon":0},{"id":"2602356518","title":"东亚药业跌3.55% 2020年上市2募资共15.74亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2602356518","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602356518?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:23","pubTimestamp":1768209784,"startTime":"0","endTime":"0","summary":"中国经济网北京1月12日讯 东亚药业 今日股价下跌,截至收盘,报20.36元,跌幅3.55%。目前该股处于破发状态。 东亚药业于2020年11月25日在上交所主板上市,发行价格为31.13元/股。2021年2月8日,东亚药业盘中跌破发行价。 东亚药业发行费用合计1.02亿元,其中,保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万元。 经计算,公司上市以来共募资2次,共计15.74亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260112/31934706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2602536846","title":"每周股票复盘:东亚药业(605177)股东户数增1.84%,可转债转股1,154,070股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536846?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:38","pubTimestamp":1768073890,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,东亚药业报收于21.11元,较上周的17.8元上涨18.6%。本周,东亚药业1月9日盘中最高价报21.3元。公司公告汇总:东亚转债累计转股1,154,070股,占转股前总股本的1.0159%。股本股东变化股东户数变动截至2025年12月31日,公司股东户数为1.06万户,较12月20日增加192.0户,增幅1.84%。户均持股数量由上期的1.1万股下降至1.08万股,户均持股市值为19.25万元。本季度内,1,000元可转债完成转股,对应转股49股。公司总股本因转股增至114,726,070股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2601400228","title":"东亚药业(605177)12月31日股东户数1.06万户,较上期增加1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601400228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601400228?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:38","pubTimestamp":1767605910,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2025年12月31日公司股东户数为1.06万户,较12月20日增加192.0户,增幅为1.84%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至12月31日,化学制药行业平均股东户数为3.44万户。从股价来看,2025年12月20日至2025年12月31日,东亚药业区间跌幅为4.25%,在此期间股东户数增加192.0户,增幅为1.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2600399670","title":"每周股票复盘:东亚药业(605177)东亚转债或触转股价格修正条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2600399670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600399670?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:04","pubTimestamp":1767297854,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,东亚药业报收于18.06元,较上周的18.59元下跌2.85%。本周,东亚药业12月22日盘中最高价报18.77元。12月26日盘中最低价报18.03元。东亚药业当前最新总市值20.42亿元,在化学制药板块市值排名149/150,在两市A股市值排名5062/5181。本周关注点公司公告汇总:东亚转债已连续10个交易日收盘价低于转股价格90%,可能触发向下修正条件。公司将按规定在触发条件当日召开董事会审议是否修正转股价格,并及时披露相关信息。敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2595677817","title":"东亚药业(605177)披露关于“东亚转债”预计满足转股价格修正条件的提示性公告,12月31日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595677817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595677817?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:07","pubTimestamp":1767175627,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,东亚药业报收于17.8元,较前一交易日下跌0.39%,最新总市值为20.42亿元。该股当日开盘17.91元,最高17.93元,最低17.63元,成交额达2282.58万元,换手率为1.14%。公司近日发布公告称,截至2025年12月30日,公司股票自12月12日起已有10个交易日收盘价低于当期转股价格20.28元/股的90%。若后续股价持续低于该标准,可能触发转股价格向下修正条件。公司将按规定在触发条件当日召开董事会审议是否修正转股价格,并及时披露相关信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2594247495","title":"每周股票复盘:东亚药业(605177)调整治理结构并优化募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2594247495","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594247495?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:27","pubTimestamp":1766870831,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,东亚药业报收于18.06元,较上周的18.59元下跌2.85%。本周,东亚药业12月22日盘中最高价报18.77元。本周关注点公司公告汇总:东亚药业取消监事会并修订公司章程。东亚药业2025年第一次临时股东大会于同日召开,审议通过调整首次公开发行股票募投项目中研发中心建设项目用途、可转换公司债券募投项目结项并将节余募集资金永久补充流动资金、取消监事会并修订《公司章程》等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2594306462","title":"东亚药业(605177)披露取消监事会并修订公司章程议案获通过,12月25日股价下跌0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594306462","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594306462?lang=zh_cn&edition=full","pubTime":"2025-12-25 23:07","pubTimestamp":1766675240,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘,东亚药业报收于18.16元,较前一交易日下跌0.06%,最新总市值为20.83亿元。该股当日开盘18.18元,最高18.3元,最低18.1元,成交额达2249.4万元,换手率为1.1%。根据近日发布的公告,浙江东亚药业股份有限公司于2025年12月25日召开2025年第一次临时股东大会,审议通过了关于取消公司监事会并修订《公司章程》的议案。本次股东大会采用现场与网络投票相结合的方式进行,表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2592193234","title":"东亚药业(605177)披露拟调整研发中心募投项目用途,12月19日股价上涨2.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592193234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592193234?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:05","pubTimestamp":1766156711,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,东亚药业报收于18.59元,较前一交易日上涨2.37%,最新总市值为21.33亿元。该股当日开盘18.16元,最高18.65元,最低18.12元,成交额达2858.24万元,换手率为1.38%。此次调整有助于提高资产使用效率和办公集中性,不影响募投项目实施,不损害公司及股东利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900040696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2590434213","title":"东亚药业(605177)披露召开2025年第一次临时股东大会通知,12月09日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590434213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590434213?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:31","pubTimestamp":1765290671,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,东亚药业报收于19.4元,较前一交易日下跌0.77%,最新总市值为22.26亿元。近日,东亚药业发布关于召开2025年第一次临时股东大会的通知。公告显示,浙江东亚药业股份有限公司将于2025年12月25日召开2025年第一次临时股东大会,会议采用现场投票与网络投票相结合的方式,网络投票通过上海证券交易所系统进行。股权登记日为2025年12月19日,股东可于2025年12月24日前办理登记。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900041339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2585605106","title":"每周股票复盘:东亚药业(605177)推进原料药制剂一体化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2585605106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585605106?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:35","pubTimestamp":1763843711,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,东亚药业报收于19.26元,较上周的21.34元下跌9.75%。本周,东亚药业11月17日盘中最高价报21.55元。公司将在胃肠道疾病、慢性肾病、消炎止痛类、抗感染类等14个疾病领域进行研发布局,并适时调整产品结构。当前在胃肠道疾病、慢性肾病、消炎止痛、抗感染等14个领域布局研发,2025年内原料药与制剂均有新产品获CDE受理,正推进商业化生产与市场推广。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2583654490","title":"每周股票复盘:东亚药业(605177)将举办2025年Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654490","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654490?lang=zh_cn&edition=full","pubTime":"2025-11-16 05:04","pubTimestamp":1763240656,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,东亚药业报收于21.34元,较上周的21.15元上涨0.9%。本周,东亚药业11月14日盘中最高价报21.59元。11月10日盘中最低价报20.77元。东亚药业当前最新总市值24.48亿元,在化学制药板块市值排名147/151,在两市A股市值排名4971/5165。公司董事长兼总经理池骋、独立董事冯燕、财务负责人王小敏、董事会秘书周剑波将出席,就公司经营业绩、发展战略等与投资者交流。会前提问通道开放至11月21日。说明会结束后可通过平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2582367995","title":"东亚药业(605177)披露举办2025年第三季度业绩说明会的公告,11月11日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367995","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582367995?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:33","pubTimestamp":1762871619,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘,东亚药业报收于21.08元,较前一交易日上涨0.81%,最新总市值为24.18亿元。该股当日开盘20.91元,最高21.14元,最低20.79元,成交额达3195.81万元,换手率为1.35%。近日,东亚药业发布公告称,公司将于2025年11月21日10:00-11:00通过价值在线平台举办2025年第三季度业绩说明会,采用视频结合网络文字互动方式。投资者可通过指定网址或微信小程序参与互动,会前提问通道开放至11月21日。说明会结束后,会议内容可通过平台查看。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2582861055","title":"每周股票复盘:东亚药业(605177)股东户数增至1.11万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861055?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:27","pubTimestamp":1762633629,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,东亚药业报收于21.15元,较上周的20.45元上涨3.42%。本周,东亚药业11月6日盘中最高价报21.25元。东亚药业当前最新总市值24.26亿元,在化学制药板块市值排名146/151,在两市A股市值排名4951/5166。户均持股数量由上期的1.05万股下降至1.04万股,户均持股市值为21.17万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770146933049,"stockEarnings":[{"period":"1week","weight":-0.0467},{"period":"1month","weight":0.2045},{"period":"3month","weight":0.0161},{"period":"6month","weight":0.0258},{"period":"1year","weight":0.2025},{"period":"ytd","weight":0.2045}],"compareEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":0.0249},{"period":"3month","weight":0.0248},{"period":"6month","weight":0.1176},{"period":"1year","weight":0.2514},{"period":"ytd","weight":0.0249}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江东亚药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9845人(较上一季度减少1.45%)","perCapita":"11435股","listingDate":"2020-11-25","address":"浙江省台州市三门县浦坝港镇沿海工业城","registeredCapital":"11472万元","survey":" 浙江东亚药业股份有限公司的主营业务是化学原料药、医药中间体的研发、生产和销售。公司的主要产品是细菌类药物(β-内酰胺类和喹诺酮类)、抗胆碱和合成解痉药物(马来酸曲美布汀)、皮肤用抗真菌药物。公司是浙江省专利示范企业,并多次承担省级重大科技专项、国家火炬计划项目、省重大国际科技专项、省重点高新技术产品开发项目等。公司“β-内酰胺类药物创新团队”于2014年入选台州市重点企业技术创新团队,多次获得浙江省和台州市科技进步奖等。报告期内,公司全资子公司杭州善礼获得中国合格评定国家认可委员会(CNAS)实验室认可证书。","listedPrice":31.13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东亚药业,605177,东亚药业股票,东亚药业股票老虎,东亚药业股票老虎国际,东亚药业行情,东亚药业股票行情,东亚药业股价,东亚药业股市,东亚药业股票价格,东亚药业股票交易,东亚药业股票购买,东亚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}